Avastin (Bevacizumab) is approved for:
- Metastatic colorectal cancer (mCRC)
- Advanced nonsquamous non–small cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel in people who have not received chemotherapy for their advanced disease.
- Metastatic kidney cancer (mRCC) when used with interferon alfa.
- Glioblastoma (GBM) when taken alone in adult patients whose cancer has progressed after prior treatment. The effectiveness of Avastin in GBM is based on tumor response.
Avastin is designed to directly bind to VEGF extracellularly
to prevent interaction with
VEGF receptors (VEGFR) on the surface of
endothelial cells, thereby inhibiting its biologic
activity.VEGFR is the family of receptors primarily responsible for pro-angiogenic VEGF
signaling. Extracellular VEGF binding may provide specific inhibition of the VEGF pathway.
Reference:
http://www.avastin-hcp.com/mrcc/efficacy/role-of-VEGF
http://www.avastin.com/patient
No comments:
Post a Comment